Company Overview and News

 
Bank of New York Mellon Corp's (BK) CEO Charles Scharf on Q1 2018 Results - Earnings Call Transcript

7h seekingalpha
The Bank of New York Mellon Corporation (NYSE:BK) Q1 2018 Earnings Conference Call April 19, 2018 8:00 AM ET
Upvote Downvote

 
BNY Mellon's (BK) Q1 Earnings Beat Estimates, Expenses Up

10h zacks
The Bank of New York Mellon Corporation’s (BK - Free Report) first-quarter 2018 earnings per share of $1.10 surpassed the Zacks Consensus Estimate of 97 cents. Also, the figure reflects an improvement of 32.5% from the prior-year quarter. Shares of the company have gained more than 3% in pre-market trading. It appears that investors are encouraged with growth in its net interest revenues as well as fee revenues.
Upvote Downvote

 
BNY Mellon (BK) Beats on Q1 Earnings as Revenues Improve

13h zacks
Have you been eager to see how The Bank of New York Mellon Corporation (BK - Free Report) performed in Q1 in comparison with the market expectations? Let’s quickly scan through the key facts from this New York-based financial services company’s earnings release this morning: Earnings Beat BNY Mellon came out with earnings of $1.10 per share, surpassing the Zacks Consensus Estimate of 97 cents. The figure was up 33% from the prior year quarter.
Upvote Downvote

 
BRIEF-Bank Of New York Mellon Corp - Quarterly Common Stock Dividend Of $0.24 Per Share

14h reuters
* BANK OF NEW YORK MELLON CORP - QUARTERLY COMMON STOCK DIVIDEND OF $0.24 PER SHARE Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)
Upvote Downvote

 
BRIEF-Bny Mellon Reports First Quarter 2018 Earnings Of $1.14 Billion Or $1.10 Per Common Share

14h reuters
* BNY MELLON REPORTS FIRST QUARTER 2018 EARNINGS OF $1.14 BILLION OR $1.10 PER COMMON SHARE
Upvote Downvote

 
BK / Bank of New York Mellon Corp. (The) FORM 8-K (Current Report)

14h sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Upvote Downvote

 
Higher Fee Revenues to Aid State Street's (STT) Q1 Earnings

2018-04-18 zacks
State Street (STT - Free Report) is scheduled to report first-quarter 2018 results before the market opens on Apr 20. Its quarterly earnings and revenues are expected to grow year over year. Last quarter, an increase in revenues drove the company’s operating earnings growth. In fact, the figure outpaced the Zacks Consensus Estimate. However, a decline in trading servicing fees was on the downside. State Street boasts an impressive earnings surprise history.
Upvote Downvote

 
Can Loan Growth Benefit People's United (PBCT) Q1 Earnings?

2018-04-18 zacks
People's United Financial, Inc. (PBCT - Free Report) is scheduled to report first-quarter 2018 results on Apr 19, before the market opens. Both revenues and earnings are anticipated to improve year over year. Before we discuss the factors that could influence the results, let’s take a look at how the company performed in the last quarter. Driven by higher revenues and lower provisions, People's United reported a positive earnings surprise of 11.
Upvote Downvote

 
Regions Financial (RF) Q1 Earnings: A Beat in the Cards?

2018-04-18 zacks
Regions Financial (RF - Free Report) is scheduled to report first-quarter 2018 results on Apr 20, before the opening bell. Both revenues and earnings are estimated to rise year over year, with a likely earnings beat in the cards. Before we discuss why an earnings beat is likely and what could influence the results, let’s take a look at how the company performed in the last reported quarter. This Birmingham, AL-based company’s fourth-quarter 2017 earnings outpaced the Zacks Consensus Estimate and compared favorably with the prior-year quarter’s earnings as well.
Upvote Downvote

 
Major Banks Q1 Earnings: Key Predictions for KEY, BBT, BK

2018-04-18 zacks
Earnings season for banks has already begun and the results released so far by the big names reflect a decent performance. The results till now indicate higher revenues supported by improved loan balances, hike in interest rates and rebound in trading activities. However, lower mortgage income and dismal investment banking performance adversely impacted fee income to some extent. On the cost front, the chance of a significant rise in expenses is low, though a marginal increase in expenses is expected to occur owing to efforts to digitize operations and investment in franchise.
Upvote Downvote

 
Ericsson (ERIC) Q1 Earnings: What Lies Ahead for the Stock?

2018-04-17 zacks
Ericsson (ERIC - Free Report) is scheduled to report first-quarter 2018 results before the opening bell on Apr 20. The company has a woeful earnings history, with consecutive colossal earnings misses. Last quarter, the company missed estimates for the eighth consecutive quarter, recording a massive negative surprise of 450%. Ericsson witnessed an average negative surprise of 552.5% for the trailing four quarters.
Upvote Downvote

 
Will Loan Growth, Lower Costs Aid KeyCorp (KEY) Q1 Earnings?

2018-04-17 zacks
KeyCorp (KEY - Free Report) , slated to announce first-quarter 2018 results on Apr 19, is expected to show improvement in net interest income (NII), driven by higher interest rates. Per the Fed’s latest data, commercial and industrial loans recorded solid growth year over year, even though the quarter witnessed a modest improvement in lending activities. The Zacks Consensus Estimate for average total loans of $87.
Upvote Downvote

 
Can Fee Income Growth Aid U.S. Bancorp's (USB) Q1 Earnings?

2018-04-17 zacks
U.S. Bancorp (USB - Free Report) is scheduled to report first-quarter 2018 results on Apr 18, before the opening bell. The bank’s revenues and earnings are anticipated to be up year over year.
Upvote Downvote

 
Can Loan Growth & Insurance Fees Aid BB&T (BBT) Q1 Earnings?

2018-04-17 zacks
BB&T Corporation (BBT - Free Report) is scheduled to report first-quarter 2018 results on Apr 19, before the market opens. Per the Fed’s latest data, commercial and industrial loans recorded solid growth on a sequential basis, though the quarter witnessed an overall modest improvement in lending activities. In fact, BB&T expects total average loans, on an annualized basis, to grow 1-3% sequentially in the to-be-reported quarter.
Upvote Downvote

 
Why is an Earnings Beat Likely for BNY Mellon (BK) in Q1?

2018-04-17 zacks
The Bank of New York Mellon Corporation (BK - Free Report) is scheduled to report first-quarter 2018 results on Apr 19, before market open. Its revenues and earnings are expected to grow year over year. Last quarter, the company’s adjusted earnings were in-line with the Zacks Consensus Estimate. Higher net interest revenues and assets under management (AUM) growth were offset by lower fee income and rise in expenses.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 064058100